Drug Profile
Research programme: cancer therapeutics - Avalon/ChemDiv
Latest Information Update: 19 Feb 2010
Price :
$50
*
At a glance
- Originator Avalon Pharmaceuticals; ChemDiv
- Developer ChemDiv; Clinical Data
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 21 Aug 2009 Preclinical development is ongoing in USA
- 29 May 2009 Avalon Pharmaceuticals has been acquired and merged into Clinical Data
- 09 Oct 2008 Preclinical development is ongoing in USA